MX2022013006A - Inhibidor de bcl-2. - Google Patents
Inhibidor de bcl-2.Info
- Publication number
- MX2022013006A MX2022013006A MX2022013006A MX2022013006A MX2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A MX 2022013006 A MX2022013006 A MX 2022013006A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- inhibitor
- compound
- disclosed
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020084992 | 2020-04-15 | ||
| CN2020100472 | 2020-07-06 | ||
| CN2020125580 | 2020-10-30 | ||
| CN2021075831 | 2021-02-07 | ||
| CN2021086189 | 2021-04-09 | ||
| PCT/CN2021/087225 WO2021208963A1 (en) | 2020-04-15 | 2021-04-14 | Bcl-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013006A true MX2022013006A (es) | 2023-01-11 |
Family
ID=78083530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013006A MX2022013006A (es) | 2020-04-15 | 2021-04-14 | Inhibidor de bcl-2. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12286430B2 (enExample) |
| EP (1) | EP4136084A4 (enExample) |
| JP (1) | JP7839962B2 (enExample) |
| KR (1) | KR20230002419A (enExample) |
| CN (3) | CN116969937B (enExample) |
| AU (1) | AU2021256580A1 (enExample) |
| BR (1) | BR112022019525A2 (enExample) |
| CA (1) | CA3172478A1 (enExample) |
| IL (1) | IL296582A (enExample) |
| MX (1) | MX2022013006A (enExample) |
| TW (1) | TW202200574A (enExample) |
| WO (1) | WO2021208963A1 (enExample) |
| ZA (1) | ZA202209891B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| CN116981668A (zh) * | 2021-04-09 | 2023-10-31 | 百济神州(北京)生物科技有限公司 | 制备bcl-2抑制剂的中间体的方法 |
| WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| JP2024540590A (ja) * | 2021-11-20 | 2024-10-31 | フォチョン・バイオサイエンシーズ・リミテッド | Ｂｃｌ－２阻害剤としての化合物 |
| JP7765790B2 (ja) * | 2021-12-06 | 2025-11-07 | 杭州和正医薬有限公司 | 抗アポトーシスタンパク質ｂｃｌ－２阻害剤、医薬組成物及びその使用 |
| WO2023122000A1 (en) * | 2021-12-20 | 2023-06-29 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| CN114292192A (zh) * | 2022-01-17 | 2022-04-08 | 山东泓瑞医药科技股份公司 | 一种3,4-二甲氧基苯甲酸甲酯的合成方法 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023231777A1 (en) * | 2022-06-01 | 2023-12-07 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| BRPI0514504A (pt) | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| EP1888543B1 (en) | 2005-05-24 | 2012-08-01 | Abbott Laboratories | Apoptosis promoters |
| MX2009002422A (es) | 2006-09-05 | 2009-03-20 | Abbott Lab | Inhibidores bcl para tratar exceso de plaquetas. |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| US8501992B2 (en) | 2008-06-09 | 2013-08-06 | Bristol-Myers Squibb Company | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| NZ614305A (en) | 2008-12-05 | 2015-03-27 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CN102307862A (zh) | 2008-12-08 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 用于治疗癌症的化合物 |
| NZ616828A (en) | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2546294T7 (es) | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| BR112012005343A2 (pt) | 2009-09-10 | 2016-03-22 | Novartis Ag | sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer |
| AU2011229862B2 (en) | 2010-03-25 | 2014-07-24 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| IT1403156B1 (it) | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
| KR101762724B1 (ko) | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| CN103732589B (zh) | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
| WO2013053045A1 (en) | 2011-10-12 | 2013-04-18 | Beta Pharma Canada Inc. | Heterocyclic molecules as apoptosis inducers |
| JP2015507741A (ja) | 2011-12-22 | 2015-03-12 | サン−ゴバン セラミックス アンド プラスティクス，インコーポレイティド | 蓄積蛍光体粉末を含む画像蓄積装置、画像蓄積装置の形成方法、およびコンピューテッドラジオグラフィ装置 |
| AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| AU2012355613A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| CA2859873A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| EA201491265A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
| WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| EP2945940B1 (en) | 2013-01-16 | 2020-07-15 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| WO2015061752A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| SMT202100674T1 (it) | 2014-08-11 | 2022-01-10 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2 |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| KR102376764B1 (ko) | 2016-08-05 | 2022-03-18 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| CN109641897B (zh) | 2016-09-01 | 2021-12-07 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
| CN106565706B (zh) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| CN106749233B (zh) * | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
| CN108046014B (zh) * | 2017-01-03 | 2019-06-18 | 惠州市盈晖电子有限公司 | 一种多种厚度规格的新旧smt接料带的粘接机 |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| JP7374496B2 (ja) | 2017-06-26 | 2023-11-07 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 |
| MX2020002032A (es) | 2017-08-23 | 2020-09-17 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de bcl-2. |
| FR3072679B1 (fr) | 2017-10-25 | 2020-10-30 | Servier Lab | Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN110143974B (zh) | 2018-02-11 | 2021-07-13 | 中国科学院上海药物研究所 | 一类新型青蒿素衍生物、合成方法及其用途 |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| WO2020140005A2 (en) * | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| CN116969937B (zh) * | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| CN116981668A (zh) * | 2021-04-09 | 2023-10-31 | 百济神州(北京)生物科技有限公司 | 制备bcl-2抑制剂的中间体的方法 |
| MX2023014275A (es) | 2021-06-02 | 2024-03-06 | Beigene Switzerland Gmbh | Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2. |
| MX2024002465A (es) | 2021-08-31 | 2024-04-29 | Beigene Ltd | Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. |
| TW202400163A (zh) | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法 |
| KR20250079128A (ko) | 2022-07-21 | 2025-06-04 | 베이진 스위찰랜드 게엠베하 | Bcl-2 저해제를 사용한 다발성 골수종의 치료 방법 |
-
2021
- 2021-04-14 CN CN202310560508.6A patent/CN116969937B/zh active Active
- 2021-04-14 BR BR112022019525A patent/BR112022019525A2/pt unknown
- 2021-04-14 MX MX2022013006A patent/MX2022013006A/es unknown
- 2021-04-14 WO PCT/CN2021/087225 patent/WO2021208963A1/en not_active Ceased
- 2021-04-14 JP JP2022554627A patent/JP7839962B2/ja active Active
- 2021-04-14 IL IL296582A patent/IL296582A/en unknown
- 2021-04-14 KR KR1020227035815A patent/KR20230002419A/ko active Pending
- 2021-04-14 CN CN202180029718.1A patent/CN116802179A/zh active Pending
- 2021-04-14 CN CN202310559385.4A patent/CN116969936A/zh active Pending
- 2021-04-14 AU AU2021256580A patent/AU2021256580A1/en active Pending
- 2021-04-14 US US17/916,845 patent/US12286430B2/en active Active
- 2021-04-14 CA CA3172478A patent/CA3172478A1/en active Pending
- 2021-04-14 TW TW110113455A patent/TW202200574A/zh unknown
- 2021-04-14 EP EP21789482.3A patent/EP4136084A4/en active Pending
-
2022
- 2022-09-05 ZA ZA2022/09891A patent/ZA202209891B/en unknown
-
2024
- 2024-03-01 US US18/593,497 patent/US20240376097A1/en not_active Abandoned
-
2025
- 2025-01-23 US US19/035,219 patent/US20250270210A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202200574A (zh) | 2022-01-01 |
| BR112022019525A2 (pt) | 2023-11-14 |
| CN116969937A (zh) | 2023-10-31 |
| CN116969936A (zh) | 2023-10-31 |
| EP4136084A1 (en) | 2023-02-22 |
| CA3172478A1 (en) | 2021-10-21 |
| JP2023520843A (ja) | 2023-05-22 |
| US20250270210A1 (en) | 2025-08-28 |
| JP7839962B2 (ja) | 2026-04-03 |
| IL296582A (en) | 2022-11-01 |
| US12286430B2 (en) | 2025-04-29 |
| US20240376097A1 (en) | 2024-11-14 |
| AU2021256580A1 (en) | 2022-09-29 |
| US20230159522A1 (en) | 2023-05-25 |
| KR20230002419A (ko) | 2023-01-05 |
| CN116969937B (zh) | 2026-03-24 |
| ZA202209891B (en) | 2023-05-31 |
| EP4136084A4 (en) | 2023-11-01 |
| CN116802179A (zh) | 2023-09-22 |
| WO2021208963A1 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| WO2024026433A3 (en) | Novel dpp1 inhibitors and uses thereof | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| BR112022019525A2 (pt) | Composto, composição farmacêutica e método para tratar doenças apoptóticas desreguladas | |
| MY138732A (en) | Conjugated complement cascade inhibitors | |
| PH12022550124A1 (en) | Enzyme inhibitors | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2025010157A (es) | Metodo de preparacion y uso de un derivado de dihidrotienopirimidina | |
| PH12022550045A1 (en) | Plasma kallikrein inhibitors | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| WO2022119858A8 (en) | Compounds for the treatment of sars | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| WO2024026486A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026483A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026479A3 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2025013435A (es) | Derivados de carboxamida heteroaromatica como inhibidores de la calicreina plasmatica | |
| WO2024026484A3 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2022014303A (es) | Compuestos para el tratamiento del sars. | |
| WO2019195641A3 (en) | 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2022014109A (es) | Uso de compuestos para el tratamiento de infecciones virales. | |
| MX2024012892A (es) | Inhibidores de kit |